H.C. Wainwright analyst Raghuram Selvaraju started Sensus Healthcare with a Buy rating and $14 price target. Superficial radiation therapy provides a better aesthetic outcome than surgical options in non-melanoma skin cancers, Selvaraju tells investors in a research note. He calls Sensus a commercial-stage medical device company with growing revenues.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.